Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2F2 | P24468 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | XBP1 | P17861 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 15/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FOS | P01100 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26159741 | 1.00 | NR2F2 (0.52) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL29501912 | 1.00 | NR2F2 (0.52) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL29501909 | 1.00 | NR2F2 (0.52) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL26159745 | 1.00 | NR2F2 (0.52) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL10050288 | 0.94 | NR2F2 (0.56) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL23452672 | 0.90 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL20329838 | 0.90 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL20299341 | 0.90 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL30736374 | 0.90 | NR2F2 (0.53) | NR2F2NPSR1KDM4EMAPTMAPK1 | |
| SCHEMBL761164 | 0.90 | NR2F2 (0.60) | NR2F2NPSR1KDM4EMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-110177791-B | Amino-triazolopyridine compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021209055-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-10-21 | — | — | WO | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2020-02-13 | — | — | US | disclosed |
| EP-3558997-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | NR2F2 3398/4885NPSR1 2545/4885KDM4E 3146/4885 |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-20200048281-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | NR2F2 3206/4885NPSR1 3142/4885KDM4E 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.